BRIEF published on 05/18/2026 at 07:35, 5 months 15 days ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
PRESS RELEASE published on 05/18/2026 at 07:30, 5 months 15 days ago Inside Information / Other news releases Sensorion appoints Fred Chereau as Chief Executive Officer, bringing extensive leadership experience in gene therapy and rare diseases. Amit Munshi continues as Chairman of the Board Gene Therapy Chief Executive Officer Rare Diseases Sensorion Fred Chereau
BRIEF published on 05/13/2026 at 07:35, 5 months 20 days ago Results of the Sensorion General Meeting Biotechnology General Assembly Resolutions Adopted Hearing Loss Sensory
PRESS RELEASE published on 05/13/2026 at 07:30, 5 months 20 days ago Inside Information / Other news releases Sensorion releases results of Combined General Meeting resolutions. All recommended resolutions adopted with 77.83% capital presence. Details available on website Shareholders General Meeting Resolutions Sensorion Hearing Loss
BRIEF published on 05/05/2026 at 07:35, 5 months 28 days ago Sensorion Participates in ASGCT Annual Meeting Biotechnology Gene Therapy Sensorion Hearing Loss ASGCT 2026
BRIEF published on 05/05/2026 at 07:35, 5 months 28 days ago Sensorion is participating in the ASGCT annual conference Gene Therapy Hearing Loss SENS-601 Sensory ASGCT 2026
PRESS RELEASE published on 05/05/2026 at 07:30, 5 months 28 days ago Inside Information / Other news releases Sensorion announces participation in ASGCT Annual Meeting to present gene therapy treatments for hereditary deafness Gene Therapy Innovative Treatments Sensorion ASGCT Annual Meeting Hereditary Deafness
BRIEF published on 04/21/2026 at 07:35, 6 months 11 days ago Sensorion is preparing for its Annual General Meeting Shareholders General Assembly Preparatory Documents Remote Voting Sensory
PRESS RELEASE published on 04/21/2026 at 07:30, 6 months 11 days ago Terms of availability of the preparatory documents for the GM Sensorion provides Preliminary Documents for the Combined Shareholders' General Meeting of May 11, 2026. Shareholders urged to participate in a critical meeting addressing new therapies for hearing loss disorders Biotechnology Shareholders' Meeting Gene Therapy Sensorion Hearing Loss
BRIEF published on 03/23/2026 at 07:35, 7 months 10 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
Published on 11/02/2026 at 15:00, 33 minutes ago CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 1 hour 33 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 1 hour 33 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 2 hours 3 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 13:30, 2 hours 3 minutes ago Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
Published on 11/02/2026 at 15:19, 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/02/2026 at 15:18, 15 minutes ago aap Implantate AG: Focus on the trauma business – fully MDR-certified portfolio, new products, expanded sales activities – capital increase to finance the next phase of growth
Published on 11/02/2026 at 15:25, 8 minutes ago Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026
Published on 10/30/2026 at 23:00, 2 days 16 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 21 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 3 hours ago Capital increase through exercise of subscription rights
